| Gene Symbol | RAB27A |
| Aliases | Ras-Related Protein Rab-27A |
| Protein Type | Signaling Protein |
| Target Class | Signaling Protein |
| Function | RAB27A regulates multiple trafficking pathways: |
| Mechanism of Action | RAB27A inhibitors would block GTP binding or GTPase activity, preventing the recruitment of effector proteins required for vesicular trafficking and exosome biogenesis. This would reduce the release of extracellular vesicles and potentially modulate intercellular communication in disease states involving excessive exosome-mediated signaling or pathological cargo transfer. |
| Druggability | Low (0.35) |
| Clinical Stage | Phase II |
| Molecular Weight | 25 kDa |
| Pathways | Mitochondrial dynamics / bioenergetics, Multivesicular Endosome Docking |
| UniProt ID | H3BS49 |
| GeneCards | RAB27A |
| Human Protein Atlas | RAB27A |
| PD Feature | RAB27A Relationship |
| [Alpha-synuclein](/proteins/alpha-synuclein) pathology | RAB27A in Lewy bodies |
| Associated Diseases | neurodegeneration |
| Known Drugs/Compounds | Nexinhib20 |
| Interactions | LATS2, COL4A1, SQSTM1, SERPINE1, LAMP1, ARSA |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | RAB27A-dependent extracellular vesicle engineering |
| KG Connections | 195 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |